Merck to Acquire Cidara in $9.2B Deal, Targeting Next-Gen Flu Drugs

Pharma giant Merck has announced a $9.2 billion acquisition of Cidara Therapeutics, aiming to boost its vaccine and antiviral portfolio with a powerful new flu drug. The deal is seen as a key move in the high-stakes race against evolving influenza threats, with the newly acquired pipeline expected to accelerate delivery of more effective treatments. Industry analysts underline the growing importance of biotechnology partnerships in addressing global health risks and adapting to an increasingly complex infectious disease landscape.

Interested in medical innovation? Watch how this acquisition could change the future of flu prevention!